Needham raised the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $80 and keeps a Buy rating on the shares after its Q4 results. At $116M, Casgevy sales in 2025 exceeded Vertex’s stated target of about $100M, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics price target raised to $45 from $40 at TD Cowen
- CRISPR Therapeutics: Casgevy Outperformance and Advancing In Vivo Pipeline Underpin Buy Rating
- Crispr Therapeutics price target lowered to $86 from $89 at BofA
- CRISPR Therapeutics: Buy-Rated, Multi-Franchise Gene-Editing Platform with Strengthening CASGEVY Launch and Catalyst-Rich 2026 Outlook
- Maintaining a Hold: Casgevy Outperformance Balanced by Pipeline Execution Risks and Limited Valuation Upside